Atrion in $24.5 million deal for Quest cardiovascular lines
This article was originally published in Clinica
Executive Summary
Atrion has agreed to buy Quest Medical's cardiovascular and intravenous fluid delivery product lines for $24.5 million in cash. Atrion will also get Quest's 27 patents relating to the products and will lease Quest's factory in Texas where the products are made - with an option to buy the plant for a further $6.5 million.